HeartFirst resource · Lp(a)

Lp(a): inherited risk
standard cholesterol can miss.

Lipoprotein(a) (Lp(a)) is a largely inherited cardiovascular risk marker. HeartFirst often calls it stealth cholesterol because a standard cholesterol panel does not include it unless it is ordered separately.
Last updated: May 2026 | Clinically reviewed: Dr. A. Sharma, Preventive Cardiology

Use the Clarity Check Read about Lp(a)
Fast orientation

Four facts to orient quickly.

Lp(a) is not a reason to panic. It is a reason to clarify your risk picture, record the result correctly, and discuss the wider prevention context with your health team.

01
It is largely inherited
For most people, Lp(a) level is strongly shaped by genetics and often relatively stable over life.
02
It needs a separate test
A standard lipid panel usually reports cholesterol fractions, not Lp(a), unless Lp(a) is specifically ordered.
03
Units matter
Results may be reported in nmol/L or mg/dL. Record the value, unit, date, and lab. Do not casually convert between units.
04
Context changes action
Lp(a) matters alongside LDL-C, ApoB where measured, blood pressure, diabetes risk, family history, and other risk layers.
What Lp(a) is

Think of Lp(a) as a risk signal carried in the blood — and often carried through families.

Lp(a) is a cholesterol-carrying particle with an added protein called apolipoprotein(a). Elevated levels are associated with higher cardiovascular risk, including atherosclerotic cardiovascular disease and aortic valve stenosis.

Why it can be missed

A "normal" cholesterol panel can still be incomplete.

Standard cholesterol testing is useful. It is also limited. It can show LDL-C, HDL-C, triglycerides, and total cholesterol, but it does not automatically show Lp(a). What is Lp(a)?

This is why someone can leave routine testing reassured and still have an inherited risk layer that has not yet been measured.

Standard panel Hidden layer Separate test
Why HeartFirst cares

Lp(a) turns one person's result into a family clue.

Because Lp(a) is largely inherited, one elevated result may matter beyond the person tested. It can become a reason to ask careful questions about parents, siblings, children, premature heart disease, stroke, and valve disease.

Testing and results

The test is simple. The interpretation needs context.

Lp(a) is usually measured with a blood test. The result becomes more useful when you record it clearly and bring it into a wider prevention conversation.

Ask whether it has actually been measured
Do not assume Lp(a) was included because you had "cholesterol checked." Look for a specific Lp(a), Lipoprotein(a), or LPA result.
Capture value, unit, date, and lab
The unit matters. A result in nmol/L is not the same format as a result in mg/dL. Record the original unit and discuss interpretation with your health team.
Do not reduce action to one number
Lp(a) is one part of the risk picture. The next action depends on the result, personal history, family history, other markers, and the care context.
Health-team conversation

Useful questions to bring forward.

You do not need to arrive with a diagnosis. You need a clearer question. These are examples of questions you can adapt to your situation.

Have I had Lp(a) measured?
If yes, what was the value, unit, date, and lab? If no, would it be reasonable to test once given my history or family history?
How does this change my overall risk picture?
Ask how Lp(a) fits with LDL-C, ApoB if measured, blood pressure, diabetes risk, smoking status, kidney disease, family history, and other risk factors.
What should be optimised now?
Current prevention often focuses on lowering modifiable risk: LDL-C/ApoB burden, blood pressure, metabolic risk, smoking exposure, sleep, activity, and other factors.
Should family members be informed or tested?
Because Lp(a) is inherited, ask whether parents, siblings, children, or other relatives should consider testing or risk assessment.
Are there other tests worth discussing?
Depending on context, this might include ApoB, non-HDL-C, blood pressure assessment, diabetes markers, kidney function, imaging, or specialist referral.
What changes if therapies become available?
Ask whether emerging Lp(a)-lowering therapies, clinical trials, or future treatment pathways are relevant to your situation.
What to do now

The first response is not panic. It is preparation.

While Lp(a)-specific medicine is evolving, there are practical steps that can make the risk conversation clearer now.

Use the Known → Unknown → To discuss → Next action method.

This keeps the conversation practical and prevents one result from becoming a fog of worry.

Known: record the Lp(a) result exactly as reported, with value, unit, date, and lab. Unknown: list missing results, unclear terms, family history gaps, or questions. To discuss: bring the most important questions to your health team. Next action: choose one practical step: request testing, gather records, prepare an appointment, start an appropriate prevention habit, or discuss family testing.
Therapy horizon

Lp(a)-lowering is one of the most active frontiers in prevention.

Several targeted therapies are being studied to lower Lp(a). The critical question is not only whether a therapy lowers the number, but whether outcome trials show fewer cardiovascular events and how treatment fits into real-world care.

Do not wait passively
Future therapies matter. So do present-day risk reducers. Use today to clarify records, optimise known modifiable risks, and prepare better questions.
Outcome evidence matters
A lower Lp(a) number is promising, but prevention decisions depend on evidence that treatment improves outcomes, safety, access, and appropriate use.
Trial readiness is preparation
If trials or future therapies may be relevant, good records matter: result unit, date, history, current medicines, prior events, and health-team context.
Next resources

Use Lp(a) as a doorway into better preparation.

This page gives orientation. The next step is to turn your own results, family history, and questions into something usable.

Clarity Check

A printable worksheet for organising what you know, what needs clarification, what to discuss, and one next action.

Use the worksheet →

Research

The deeper evidence layer behind HeartFirst public education, briefings, and tools.

Go to Research →

Briefings

Short, practical summaries for quick reference, sharing, and better health-team conversations.

Browse Briefings →

Educational boundary

HeartFirst helps you understand and prepare. It does not diagnose, treat, or replace personalised medical care.

Use this page as orientation, not instruction. If symptoms may be urgent, seek urgent medical care. If you have an Lp(a) result, medication question, family history concern, or personal risk decision, discuss it with your health team.
Next

Found or suspect high Lp(a)?
Start by organising what you know.

The Clarity Check gives you a simple way to record your result, identify what is missing, prepare focused questions, and choose one useful next action.

Use the Clarity Check
Where to go next

This page meets WCAG 2.2 AA standards. All interactive elements are keyboard-navigable and screen-reader compatible.
Lp(a) testing availability, interpretation thresholds, and clinical guidance may vary by region and healthcare system. Discuss your results with your health team.